Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Licenses microRNA Sequences from Max Planck for Dx Development

NEW YORK (GenomeWeb News) - Rosetta Genomics has licensed from the Max Planck Society rights to patents covering “potentially hundreds” of human microRNA sequences for use in diagnostic applications, the company said.
 
Rosetta said it will add the sequences to its microRNA database, where they will provide the company with additional biomarker candidates for its diagnostic-development programs.
 
Under the terms of the agreement, Rosetta will be able to use the sequences in research and development programs targeting new microRNA-based diagnostic tools for a variety of diseases.
 
The company will pay an initiation fee as well as maintenance fees and royalties to the Max Planck Society. Additional financial details were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.